8.71
price down icon1.25%   -0.11
after-market 시간 외 거래: 8.60 -0.11 -1.26%
loading
전일 마감가:
$8.82
열려 있는:
$8.79
하루 거래량:
446.85K
Relative Volume:
0.52
시가총액:
$439.98M
수익:
$89.04M
순이익/손실:
$-241.08M
주가수익비율:
-1.6559
EPS:
-5.26
순현금흐름:
$-194.72M
1주 성능:
+16.76%
1개월 성능:
+6.74%
6개월 성능:
+14.91%
1년 성능:
-28.90%
1일 변동 폭
Value
$8.61
$8.98
1주일 범위
Value
$7.533
$9.25
52주 변동 폭
Value
$5.035
$13.48

Regenxbio Inc Stock (RGNX) Company Profile

Name
명칭
Regenxbio Inc
Name
전화
240-552-8181
Name
주소
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Name
직원
353
Name
트위터
@REGENXBIO
Name
다음 수익 날짜
2025-08-01
Name
최신 SEC 제출 서류
Name
RGNX's Discussions on Twitter

RGNX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
RGNX
Regenxbio Inc
8.71 445.54M 89.04M -241.08M -194.72M -5.26
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
389.88 100.71B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
456.87 58.84B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.91 61.52B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ARGX
Argen X Se Adr
661.32 40.01B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
319.32 38.20B 3.81B -644.79M -669.77M -6.24

Regenxbio Inc Stock (RGNX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-02-11 다운그레이드 Goldman Buy → Neutral
2025-02-07 재개 Raymond James Outperform
2024-11-15 재개 Morgan Stanley Overweight
2024-10-10 재개 Raymond James Outperform
2024-06-07 개시 Goldman Buy
2024-03-11 개시 H.C. Wainwright Buy
2024-03-08 업그레이드 RBC Capital Mkts Sector Perform → Outperform
2024-03-06 업그레이드 Leerink Partners Market Perform → Outperform
2024-02-21 재개 Raymond James Outperform
2023-11-01 개시 Stifel Buy
2023-06-02 개시 Robert W. Baird Outperform
2022-06-23 개시 Berenberg Buy
2021-12-15 개시 Wedbush Neutral
2021-10-19 재개 Morgan Stanley Overweight
2021-01-06 업그레이드 Raymond James Outperform → Strong Buy
2020-12-16 개시 UBS Buy
2020-06-25 재개 BofA/Merrill Buy
2020-05-13 개시 RBC Capital Mkts Sector Perform
2019-08-20 업그레이드 SVB Leerink Underperform → Mkt Perform
2019-06-18 재확인 Chardan Capital Markets Buy
2019-06-14 재개 Raymond James Outperform
2019-06-05 재확인 Chardan Capital Markets Buy
2019-02-25 업그레이드 Evercore ISI In-line → Outperform
2019-02-05 업그레이드 Raymond James Outperform → Strong Buy
2018-12-17 재확인 Chardan Capital Markets Buy
2018-11-08 재확인 BofA/Merrill Neutral
2018-08-08 재확인 Chardan Capital Markets Buy
2018-07-23 다운그레이드 BofA/Merrill Buy → Neutral
2018-07-10 재확인 Chardan Capital Markets Buy
2018-05-09 재확인 Barclays Overweight
2018-04-09 재확인 Chardan Capital Markets Buy
2018-03-12 다운그레이드 Evercore ISI Outperform → In-line
2018-02-13 개시 Mizuho Neutral
2017-11-09 재개 Morgan Stanley Overweight
모두보기

Regenxbio Inc 주식(RGNX)의 최신 뉴스

pulisher
12:56 PM

REGENXBIO Inc. Facing Inflection Point in Trend AnalysisJuly 2025 WrapUp & Verified High Yield Trade Plans - kangso.co.kr

12:56 PM
pulisher
Aug 15, 2025

Trendline Breach Raises Concern for REGENXBIO Inc. Investors2025 Price Action Summary & Safe Capital Growth Tips - sundaytimes.kr

Aug 15, 2025
pulisher
Aug 15, 2025

Does REGENXBIO (NASDAQ:RGNX) Have A Healthy Balance Sheet? - 富途牛牛

Aug 15, 2025
pulisher
Aug 15, 2025

Technical analysis overview for REGENXBIO Inc. stock2025 Winners & Losers & Detailed Earnings Play Strategies - Newser

Aug 15, 2025
pulisher
Aug 15, 2025

Detecting price anomalies in REGENXBIO Inc. with AIJuly 2025 Movers & Real-Time Volume Analysis - Newser

Aug 15, 2025
pulisher
Aug 14, 2025

Can REGENXBIO Inc. hit a new high this monthJuly 2025 WrapUp & Expert Curated Trade Setup Alerts - Newser

Aug 14, 2025
pulisher
Aug 14, 2025

Can REGENXBIO Inc. rally from current levelsJuly 2025 Macro Moves & Advanced Technical Signal Analysis - Newser

Aug 14, 2025
pulisher
Aug 13, 2025

REGENXBIO’s SWOT analysis: gene therapy pioneer’s stock faces pivotal year - Investing.com Canada

Aug 13, 2025
pulisher
Aug 13, 2025

Is a relief rally coming for REGENXBIO Inc. holdersJuly 2025 Outlook & Technical Pattern Alert System - Newser

Aug 13, 2025
pulisher
Aug 13, 2025

When is the best time to exit REGENXBIO Inc.Weekly Trade Recap & High Accuracy Investment Entry Signals - Newser

Aug 13, 2025
pulisher
Aug 13, 2025

What makes REGENXBIO Inc. stock price move sharplyMarket Growth Review & Free Weekly Chart Analysis and Trade Guides - thegnnews.com

Aug 13, 2025
pulisher
Aug 12, 2025

Will breakout in REGENXBIO Inc. lead to full recoveryJuly 2025 Macro Moves & Verified Entry Point Signals - Newser

Aug 12, 2025
pulisher
Aug 12, 2025

Are Options Traders Betting on a Big Move in Regenxbio Stock? - TradingView

Aug 12, 2025
pulisher
Aug 12, 2025

What’s next for REGENXBIO Inc. stock priceFree Market Entry and Exit Point Tips - Newser

Aug 12, 2025
pulisher
Aug 12, 2025

Investors Don't See Light At End Of REGENXBIO Inc.'s (NASDAQ:RGNX) Tunnel - simplywall.st

Aug 12, 2025
pulisher
Aug 12, 2025

XTX Topco Ltd Reduces Stake in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World

Aug 12, 2025
pulisher
Aug 12, 2025

REGENXBIO (NASDAQ:RGNX) Cut to “Strong Sell” at Wall Street Zen - Defense World

Aug 12, 2025
pulisher
Aug 11, 2025

Dystrophin Gene Therapy Market 2025 | $12B Growth, REGENXBIO & - openPR.com

Aug 11, 2025
pulisher
Aug 10, 2025

Can REGENXBIO Inc. expand its profit marginsSafe Growth Small Cap Picks - thegnnews.com

Aug 10, 2025
pulisher
Aug 10, 2025

Royal Bank Of Canada Has Lowered Expectations for REGENXBIO (NASDAQ:RGNX) Stock Price - Defense World

Aug 10, 2025
pulisher
Aug 10, 2025

REGENXBIO (NASDAQ:RGNX) Earns Buy Rating from Chardan Capital - Defense World

Aug 10, 2025
pulisher
Aug 09, 2025

Analysts Offer Insights on Healthcare Companies: Myomo (MYO), Quoin Pharmaceuticals (QNRX) and RegenXBio (RGNX) - The Globe and Mail

Aug 09, 2025
pulisher
Aug 09, 2025

These Analysts Just Made An Incredible Downgrade To Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Forecasts - Yahoo Finance

Aug 09, 2025
pulisher
Aug 09, 2025

REGENXBIO Inc. recovery potential after sell offBuy Entry Confirmation Based on Technical Analysis - Newser

Aug 09, 2025
pulisher
Aug 09, 2025

REGENXBIO (NASDAQ:RGNX) Stock Price Passes Below Fifty Day Moving Average on Disappointing Earnings - Defense World

Aug 09, 2025
pulisher
Aug 09, 2025

REGENXBIO Reports Q2 2025 Financial Results and Progress - The Globe and Mail

Aug 09, 2025
pulisher
Aug 08, 2025

Is REGENXBIO Inc. stock a buy or sellElite Portfolio Components - thegnnews.com

Aug 08, 2025
pulisher
Aug 08, 2025

Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates - MSN

Aug 08, 2025
pulisher
Aug 08, 2025

Regenxbio accelerates RGX-202 pivotal enrollment to October 2025 as topline data targeted for early 2026 - MSN

Aug 08, 2025
pulisher
Aug 08, 2025

Raymond James Remains a Buy on RegenXBio (RGNX) - The Globe and Mail

Aug 08, 2025
pulisher
Aug 08, 2025

Regenxbio: RBC Capital Maintains Outperform, PT Down to $17 from $21 - AInvest

Aug 08, 2025
pulisher
Aug 08, 2025

Regenxbio price target lowered to $17 from $21 at RBC Capital - TipRanks

Aug 08, 2025
pulisher
Aug 08, 2025

RBC Capital lowers Regenxbio stock price target to $17 on quarterly results - Investing.com

Aug 08, 2025
pulisher
Aug 08, 2025

RBC Capital lowers Regenxbio stock price target to $17 on quarterly results By Investing.com - Investing.com South Africa

Aug 08, 2025
pulisher
Aug 08, 2025

Regenxbio's Q2 2025: Key Contradictions on RGX-121 Approval, Manufacturing Plans, and Pivotal Study Design - AInvest

Aug 08, 2025
pulisher
Aug 08, 2025

REGENXBIO Inc. (RGNX): Navigating Q2 2025 Challenges with a High-Stakes Gene Therapy Pipeline - AInvest

Aug 08, 2025
pulisher
Aug 08, 2025

RBC Cuts Price Target on REGENXBIO to $17 From $21, Keeps Outperform, Speculative Risk - MarketScreener

Aug 08, 2025
pulisher
Aug 08, 2025

Regenxbio: Chardan Capital maintains Buy, PT raised to $52 from $52. - AInvest

Aug 08, 2025
pulisher
Aug 08, 2025

Transcript : REGENXBIO Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener

Aug 08, 2025
pulisher
Aug 08, 2025

Regenxbio 2025 Q2 Earnings Wider Losses Amid Progress in Gene Therapy Pipeline - AInvest

Aug 08, 2025
pulisher
Aug 08, 2025

Regenxbio Inc (RGNX) Q2 2025 Earnings Call Highlights: Strong Financial Position and Strategic ... By GuruFocus - Investing.com Canada

Aug 08, 2025
pulisher
Aug 07, 2025

Forecasting REGENXBIO Inc. price range with options dataExit Strategy Guide With Risk Control Plan - Newser

Aug 07, 2025
pulisher
Aug 07, 2025

Regenxbio: Q2 Earnings Snapshot - Stamford Advocate

Aug 07, 2025
pulisher
Aug 07, 2025

Regenxbio Inc. shares rise 1.27% after-hours following the initiation of a pivotal Phase IIb/III clinical trial for diabetic retinopathy. - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Regenxbio stock maintains Outperform rating at Raymond James on solid cash runway - Investing.com Nigeria

Aug 07, 2025
pulisher
Aug 07, 2025

Earnings call transcript: Regenxbio Q2 2025 misses forecasts, stock dips - Investing.com

Aug 07, 2025
pulisher
Aug 07, 2025

Earnings call transcript: Regenxbio Q2 2025 misses forecasts, stock dips By Investing.com - Investing.com Canada

Aug 07, 2025
pulisher
Aug 07, 2025

Regenxbio Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 07, 2025
pulisher
Aug 07, 2025

XtalPi inks pact with Greg Verdine’s DoveTree; Regenxbio, AbbVie update deal - Endpoints News

Aug 07, 2025
pulisher
Aug 07, 2025

Regenxbio launches program for surabgene lomparvovec in diabetic retinopathy - TipRanks

Aug 07, 2025
pulisher
Aug 07, 2025

Regenxbio Incphase IIb/III trial to be initiated for diabetic retinopathy - MarketScreener

Aug 07, 2025

Regenxbio Inc (RGNX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Regenxbio Inc 주식 (RGNX) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Mills Kenneth T.
Director
May 12 '25
Sale
7.91
20,602
163,046
475,103
$35.92
price down icon 1.18%
$84.92
price down icon 2.30%
$26.29
price down icon 1.50%
$127.27
price down icon 0.41%
$112.55
price down icon 0.85%
biotechnology ONC
$319.32
price down icon 0.63%
자본화:     |  볼륨(24시간):